Cognition Therapeutics (CGTX) Competitors $0.32 +0.00 (+1.02%) Closing price 06/11/2025 04:00 PM EasternExtended Trading$0.32 +0.00 (+0.88%) As of 06/11/2025 07:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CGTX vs. ADAP, GNTA, SRZN, ABOS, SKYE, MCRB, STRO, MNOV, ANRO, and IKNAShould you be buying Cognition Therapeutics stock or one of its competitors? The main competitors of Cognition Therapeutics include Adaptimmune Therapeutics (ADAP), Genenta Science (GNTA), Surrozen (SRZN), Acumen Pharmaceuticals (ABOS), Skye Bioscience (SKYE), Seres Therapeutics (MCRB), Sutro Biopharma (STRO), MediciNova (MNOV), Alto Neuroscience (ANRO), and Ikena Oncology (IKNA). These companies are all part of the "pharmaceutical products" industry. Cognition Therapeutics vs. Its Competitors Adaptimmune Therapeutics Genenta Science Surrozen Acumen Pharmaceuticals Skye Bioscience Seres Therapeutics Sutro Biopharma MediciNova Alto Neuroscience Ikena Oncology Cognition Therapeutics (NASDAQ:CGTX) and Adaptimmune Therapeutics (NASDAQ:ADAP) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, valuation, community ranking, profitability, media sentiment and institutional ownership. Does the MarketBeat Community prefer CGTX or ADAP? Adaptimmune Therapeutics received 303 more outperform votes than Cognition Therapeutics when rated by MarketBeat users. However, 74.29% of users gave Cognition Therapeutics an outperform vote while only 63.39% of users gave Adaptimmune Therapeutics an outperform vote. CompanyUnderperformOutperformCognition TherapeuticsOutperform Votes2674.29% Underperform Votes925.71% Adaptimmune TherapeuticsOutperform Votes32963.39% Underperform Votes19036.61% Which has stronger earnings & valuation, CGTX or ADAP? Cognition Therapeutics has higher earnings, but lower revenue than Adaptimmune Therapeutics. Adaptimmune Therapeutics is trading at a lower price-to-earnings ratio than Cognition Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCognition TherapeuticsN/AN/A-$25.79M-$0.74-0.43Adaptimmune Therapeutics$179.64M0.40-$113.87M-$0.27-1.01 Is CGTX or ADAP more profitable? Cognition Therapeutics has a net margin of 0.00% compared to Adaptimmune Therapeutics' net margin of -25.43%. Adaptimmune Therapeutics' return on equity of -74.15% beat Cognition Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Cognition TherapeuticsN/A -150.93% -100.82% Adaptimmune Therapeutics -25.43%-74.15%-15.09% Which has more volatility & risk, CGTX or ADAP? Cognition Therapeutics has a beta of 0.75, meaning that its stock price is 25% less volatile than the S&P 500. Comparatively, Adaptimmune Therapeutics has a beta of 2.24, meaning that its stock price is 124% more volatile than the S&P 500. Does the media favor CGTX or ADAP? In the previous week, Cognition Therapeutics and Cognition Therapeutics both had 2 articles in the media. Cognition Therapeutics' average media sentiment score of 1.44 beat Adaptimmune Therapeutics' score of 1.14 indicating that Cognition Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Cognition Therapeutics Positive Adaptimmune Therapeutics Positive Do analysts recommend CGTX or ADAP? Cognition Therapeutics currently has a consensus price target of $5.63, suggesting a potential upside of 1,673.33%. Adaptimmune Therapeutics has a consensus price target of $1.52, suggesting a potential upside of 457.80%. Given Cognition Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Cognition Therapeutics is more favorable than Adaptimmune Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cognition Therapeutics 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.00Adaptimmune Therapeutics 1 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.43 Do insiders and institutionals hold more shares of CGTX or ADAP? 43.3% of Cognition Therapeutics shares are owned by institutional investors. Comparatively, 31.4% of Adaptimmune Therapeutics shares are owned by institutional investors. 14.4% of Cognition Therapeutics shares are owned by company insiders. Comparatively, 12.7% of Adaptimmune Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. SummaryCognition Therapeutics beats Adaptimmune Therapeutics on 10 of the 16 factors compared between the two stocks. Get Cognition Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CGTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CGTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CGTX vs. The Competition Export to ExcelMetricCognition TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$19.66M$3.09B$5.57B$8.62BDividend YieldN/A1.58%5.28%4.18%P/E Ratio-0.3333.3227.1720.06Price / SalesN/A469.84409.72157.10Price / CashN/A168.6838.2534.64Price / Book0.423.457.064.70Net Income-$25.79M-$72.35M$3.23B$247.88M7 Day Performance9.34%6.23%2.89%2.66%1 Month Performance-2.97%16.53%9.06%6.40%1 Year Performance-86.67%-16.90%31.40%14.07% Cognition Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CGTXCognition Therapeutics3.3982 of 5 stars$0.32+1.0%$5.63+1,673.3%-84.7%$19.66MN/A-0.3320Positive NewsShort Interest ↓ADAPAdaptimmune Therapeutics3.3405 of 5 stars$0.28-0.5%$1.52+439.0%-73.8%$74.67M$179.64M-1.28490Positive NewsGNTAGenenta Science2.7783 of 5 stars$4.00flat$25.00+525.0%+15.8%$73.16MN/A0.007Short Interest ↓SRZNSurrozen3.7894 of 5 stars$8.80+3.5%$38.50+337.5%-20.9%$72.78M$11.64M-0.3580Positive NewsABOSAcumen Pharmaceuticals2.4679 of 5 stars$1.27+5.8%$7.33+477.4%-57.0%$72.69MN/A-0.9220Positive NewsShort Interest ↑Analyst RevisionSKYESkye Bioscience1.792 of 5 stars$2.34-3.7%$16.60+609.4%-78.8%$72.48MN/A-2.8511Analyst RevisionGap UpMCRBSeres Therapeutics3.5536 of 5 stars$8.15-1.0%$73.67+803.9%-49.5%$71.17M$126.33M-35.43330Positive NewsSTROSutro Biopharma4.6056 of 5 stars$0.83-2.5%$6.11+639.6%-78.4%$69.82M$66.43M-0.51240Positive NewsGap DownMNOVMediciNova2.1099 of 5 stars$1.42+0.7%$9.00+533.8%+2.3%$69.65M$1M-6.1710ANROAlto Neuroscience1.6517 of 5 stars$2.55-0.8%$15.40+503.9%-79.4%$69.03MN/A-1.09N/AGap UpIKNAIkena Oncology3.6664 of 5 stars$1.47+3.5%$3.00+104.1%-22.7%$68.53M$659K-1.2070Short Interest ↓Gap Up Related Companies and Tools Related Companies Adaptimmune Therapeutics Competitors Genenta Science Competitors Surrozen Competitors Acumen Pharmaceuticals Competitors Skye Bioscience Competitors Seres Therapeutics Competitors Sutro Biopharma Competitors MediciNova Competitors Alto Neuroscience Competitors Ikena Oncology Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CGTX) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump Makes Major Crypto AnnouncementPay close attention to what I'm about to share… Most investors think Trump's pro-crypto policies will lift ...Crypto 101 Media | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredMarch 16th -- America’s most important day?50-Year Legend: Here's The Day Stocks Likely Crash Legendary quant analyst Marc Chaikin says in 50 years on...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cognition Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cognition Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CGTX Stock Free CGTX Stock Alerts